|
|||||
|
|
Update on the use of ciclosporin in immune-mediated dermatoses |
|
| Authors: | C.E.M. Griffiths,A. Katsambas,B.A.C. Dijkmans&dagger ,A.Y. Finlay&Dagger ,V.C. Ho§ ,A. Johnston¶ ,T.A. Luger,U. Mrowietz&dagger &dagger , K. Thestrup-Pedersen&Dagger &Dagger |
| Affiliation: | Dermatology Centre, University of Manchester, Hope Hospital, Manchester, UK Department of Dermatology, University of Athens, A. Sygros Hospital, Athens, Greece; Department of Rheumatology, VU Medical Centre, Amsterdam, The Netherlands; Department of Dermatology, Cardiff University, Cardiff, UK; Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada; Clinical Pharmacology, Barts and The London, University of London, UK; Department of Dermatology, University of Münster, Germany; Department of Dermatology, University of Kiel, Germany; Department of Dermatology, University of Aarhus, Denmark |
| Abstract: | Immune-mediated dermatoses, such as psoriasis and atopic dermatitis, affect a significant proportion of the population. Although most cases are not life threatening, these diseases can have a profound effect on the sufferer's quality of life and that of their family. Systemic therapy, such as ciclosporin, is often indicated for severe or recalcitrant disease. The efficacy of ciclosporin in the treatment of psoriasis and atopic dermatitis has been established and clinical data also demonstrate its efficacy in treating less common but equally challenging conditions such as pyoderma gangrenosum, lichen planus, autoimmune bullous disease, recalcitrant chronic idiopathic urticaria and chronic dermatitis of the hands and feet. The risk of potential adverse events associated with ciclosporin is greatly reduced if current treatment and monitoring guidelines are followed. |
| Keywords: | calcineurin inhibitor ciclosporin dermatoses efficacy immune-mediated safety |